Inhibikase Therapeutics Inc (IKT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $213.21M
Last updated: Nov 17, 2026 at 4:30 PM ET
Inhibikase Therapeutics Inc (IKT) Stock Chart
Inhibikase Therapeutics (IKT) has a latest price of $1.38 on Nov 17, 2026. Its price fell 9.8% over the past 12 months. The month-end price fell 87.0% over the 5 years through Oct 2026, a compound annual decline of 33.5%.
Price Chart
From Dec 2020 to Oct 2026, its highest month-end close was $41.39 in Dec 2020 and its lowest $0.89 in Oct 2023, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart IKT with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for IKT.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 43.7%, and over 6 months it fell 12.1%. The month-end price rose 75.0% over the 3 years through Oct 2026, a compound annual rate of 20.5%.
| Period | Change |
|---|---|
| 1 month | -16.1% |
| 3 months | -43.7% |
| 6 months | -12.1% |
| 12 months | -9.8% |
| 12 months, with dividends | -9.8% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +75.0% | +20.5% |
| 5 years | -87.0% | -33.5% |
Price by Year
Its best calendar year was 2024, when the price rose 155.9%, and its weakest was 2021, when it fell 78.7%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $1.55 | -24.4% |
| 2025 | $2.05 | -36.9% |
| 2024 | $3.25 | +155.9% |
| 2023 | $1.27 | -57.7% |
| 2022 | $3.00 | -66.0% |
| 2021 | $8.82 | -78.7% |
Trading Range
The price is 25.6% below its 50-day average of $1.85 and 28.5% below its 200-day average of $1.93.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $1.38 | |
| 50-day average | $1.85 | -25.6% |
| 200-day average | $1.93 | -28.5% |
Price Risk
Over 3 years, its largest fall from a peak was 65.2%.
| Measure | Value |
|---|---|
| 1-year beta | 1.66 |
| Largest fall, 1 year | -45.2% |
| Largest fall, 3 years | -65.2% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About IKT
What is IKT's 1-year price change?
Inhibikase Therapeutics's price fell 9.8% over the past 12 months. With dividends included, the 12-month total return was -9.8%.
What is IKT's 5-year price change?
Inhibikase Therapeutics's month-end price fell 87.0% over the 5 years through Oct 2026, a compound annual decline of 33.5%. These figures leave out dividends.
What is IKT's beta?
Inhibikase Therapeutics's 1-year beta against the S&P 500 is 1.66, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 45.2%.
Is the IKT chart free?
Yes. Advanced Charting for IKT is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
IKT pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors